Published in Virology on January 26, 2011
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
A viral RNA structural element alters host recognition of nonself RNA. Science (2014) 1.71
2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog (2012) 1.62
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J Virol (2012) 1.43
Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol (2012) 1.36
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
The interferon-inducible gene viperin restricts West Nile virus pathogenesis. J Virol (2011) 1.20
A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response. MBio (2013) 1.13
Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol J (2011) 1.12
Interferon regulatory factor-1 (IRF-1) shapes both innate and CD8(+) T cell immune responses against West Nile virus infection. PLoS Pathog (2011) 1.09
Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog (2014) 1.06
Genome-wide RNAi screen identifies broadly-acting host factors that inhibit arbovirus infection. PLoS Pathog (2014) 1.03
Generation and analysis of novel plant-derived antibody-based therapeutic molecules against West Nile virus. PLoS One (2014) 1.03
A role for Ifit2 in restricting West Nile virus infection in the brain. J Virol (2013) 1.00
Complement-mediated neutralization of dengue virus requires mannose-binding lectin. MBio (2011) 0.97
Mannose binding lectin is required for alphavirus-induced arthritis/myositis. PLoS Pathog (2012) 0.92
The role of humoral innate immunity in hepatitis C virus infection. Viruses (2012) 0.91
Innate immunity and neuroinflammation. Mediators Inflamm (2013) 0.90
A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature (2016) 0.87
Complement Activation by Giardia duodenalis Parasites through the Lectin Pathway Contributes to Mast Cell Responses and Parasite Control. Infect Immun (2016) 0.81
Modulation of innate immune signaling by the secreted form of the West Nile virus NS1 glycoprotein. Virology (2014) 0.80
Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. PLoS One (2014) 0.79
The Interferon-Stimulated Gene Ifi27l2a Restricts West Nile Virus Infection and Pathogenesis in a Cell-Type- and Region-Specific Manner. J Virol (2015) 0.79
The role of innate immunity in conditioning mosquito susceptibility to West Nile virus. Viruses (2013) 0.79
B cell response and mechanisms of antibody protection to West Nile virus. Viruses (2014) 0.78
The Complement System in Flavivirus Infections. Front Microbiol (2017) 0.75
Dengue Virus Glycosylation: What Do We Know? Front Microbiol (2017) 0.75
The complement system: a gateway to gene-environment interactions in schizophrenia pathogenesis. Mol Psychiatry (2017) 0.75
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol (2006) 2.25
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol (2002) 2.21
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog (2009) 1.95
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol (2008) 1.92
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol (2007) 1.89
Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol (2006) 1.86
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 1.84
Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog (2012) 1.84
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol (2005) 1.72
A viral RNA structural element alters host recognition of nonself RNA. Science (2014) 1.71
Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A (2007) 1.71
L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol (2004) 1.70
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med (2008) 1.67
IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog (2013) 1.67
Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol (2003) 1.67
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog (2012) 1.62
Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe (2012) 1.61
CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol (2008) 1.61
CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A (2008) 1.60
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. Nat Med (2013) 1.55
Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med (2011) 1.53
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol (2002) 1.52
An infectious West Nile virus that expresses a GFP reporter gene. Virology (2005) 1.51
Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology (2009) 1.50
Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J (2006) 1.49
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
Tumor necrosis factor alpha protects against lethal West Nile virus infection by promoting trafficking of mononuclear leukocytes into the central nervous system. J Virol (2008) 1.48
Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog (2013) 1.47
Endogenous MHC-related protein 1 is transiently expressed on the plasma membrane in a conformation that activates mucosal-associated invariant T cells. J Immunol (2011) 1.47
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J Virol (2012) 1.43
The essential, nonredundant roles of RIG-I and MDA5 in detecting and controlling West Nile virus infection. J Virol (2013) 1.42
Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe (2013) 1.42
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
The RIG-I-like receptor LGP2 controls CD8(+) T cell survival and fitness. Immunity (2012) 1.39
The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J Virol (2009) 1.39
Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest (2017) 1.39
The innate immune adaptor molecule MyD88 restricts West Nile virus replication and spread in neurons of the central nervous system. J Virol (2010) 1.38
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe (2007) 1.37
Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol (2012) 1.36
West Nile virus noncoding subgenomic RNA contributes to viral evasion of the type I interferon-mediated antiviral response. J Virol (2012) 1.35
Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. J Virol (2008) 1.35
Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol (2012) 1.34
Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol (2007) 1.32
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
Pathogenesis of flavivirus encephalitis. Adv Virus Res (2003) 1.30